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Inefficient skeletal muscle oxidative 
function flanks impaired motor 
neuron recruitment in Amyotrophic 
Lateral Sclerosis during exercise
F. Lanfranconi1, A. Ferri1,2, G. Corna1, R. Bonazzi1, C. Lunetta3, V. Silani4,5, N. Riva6,  
A. Rigamonti7, A. Maggiani8, C. Ferrarese1,9 & L. Tremolizzo1,9
This study aimed to evaluate muscle oxidative function during exercise in amyotrophic lateral sclerosis 
patients (pALS) with non-invasive methods in order to assess if determinants of reduced exercise 
tolerance might match ALS clinical heterogeneity. 17 pALS, who were followed for 4 months, were 
compared with 13 healthy controls (CTRL). Exercise tolerance was assessed by an incremental exercise 
test on cycle ergometer measuring peak O2 uptake (VO2peak), vastus lateralis oxidative function by near 
infrared spectroscopy (NIRS) and breathing pattern (VE peak). pALS displayed: (1) 44% lower VO2peak vs. 
CTRL (p < 0.0001), paralleled by a 43% decreased peak skeletal muscle oxidative function (p < 0.01), 
with a linear regression between these two variables (r2 = 0.64, p < 0.0001); (2) 46% reduced VEpeak vs. 
CTRL (p < 0.0001), achieved by using an inefficient breathing pattern (increasing respiratory frequency) 
from the onset until the end of exercise. Inefficient skeletal muscle O2 function, when flanking the 
impaired motor units recruitment, is a major determinant of pALS clinical heterogeneity and working 
capacity exercise tolerance. CPET and NIRS are useful tools for detecting early stages of oxidative 
deficiency in skeletal muscles, disclosing individual impairments in the O2 transport and utilization 
chain.
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder involving alpha motor neurons and 
abnormal recruitment of motor units, due to lesions in the corticospinal pathways. The resulting clinical mani-
festations of asthenia, spasticity, and amyotrophy harshly impair functional independence of patients and their 
quality of life. ALS patients (pALS) have a heterogeneous onset, with increasing fatigability that may begin with 
impaired activation of limbs, or with dysphagia or dysarthria when the bulbar district is affected first, and with 
a final failure of respiratory muscles. The appearance of ALS, from the earliest phases of the disease, also typi-
cally consists of reduced exercise tolerance until there is complete restriction of activities of daily living1–3. The 
characteristic heterogeneity in exercise tolerance of pALS is related to both the pathologic pattern of motor unit 
recruitment, and muscle impairment due to disuse of potentially healthy muscles3, 4.
The reduced exercise tolerance in pALS (i.e., the capacity to maintain workloads ranging from habitual activ-
ities to rehabilitation exercises) has been associated with mitochondrial dysfunction, both as a direct pathogenic 
mechanism and as a factor contributing to the exercise limitation5, 6. Furthermore, the degree of exercise intol-
erance in pALS might correlate with the reduction in the number and effectiveness of functional mitochondria 
able to guarantee an adequate O2 extraction at the skeletal muscles5. During the early stages (less than 9 months 
from disease onset), pALS show no evidence of mitochondrial dysfunction. However, this is clearly present 
with increasing severity and when the disease is finally identified by clinical disability scales7. Nevertheless, a 
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subclinical mitochondrial dysfunction may be present in the early stages of ALS and undetectable in resting con-
ditions, only to become apparent with additional external and environmental stress such as exercise8. In pALS this 
phenomenon has not been fully characterized in term of the underlying governing dynamics of oxidative metab-
olism, and specifically by assessing skeletal muscle oxidative function during exercise. By evaluating the balance 
between O2 delivery and O2 extraction at the skeletal muscle level (fulfilling the principle of mass conservation 
as settled by Fick equation), it is possible to obtain an indirect measure of mitochondrial function. Near infrared 
spectroscopy (NIRS) is a non-invasive method that can be used to provide an estimation of skeletal muscle frac-
tional O2 extraction during exercise in healthy participants or patients9–12. According to Ryan and colleagues13, 
NIRS is a useful technique in order to verify oxidative metabolism impairment at the mitochondrial level in the 
skeletal muscles of pALS. However, although NIRS has been used to assess skeletal muscle oxidative function, 
the use of low-intensity exercise in this study means that impairments in maximal mitochondrial function may 
have been missed. Compared to Ryan et al. report, we thought to consider an incremental exercise in order to 
determine the putative impairment of the maximal power of oxidative phosphorylation pathway. Indeed, the 
expression of integration and efficiency of our body systems is revealed only by exercise, being the resting condi-
tion a state where metabolic resources are essentially underused. An efficient chain of transport and utilization 
of O2 from ambient air to mitochondrial level is individually determinable and can be considered our oxidative 
reserve to face exercise, unless a disease compromises this wealth. In fact, during moderate- or high-intensity 
physical activities carried out for several minutes, such as activities of daily living in pALS, the oxidative metab-
olism becomes the prevalent mechanism responsible for adenosine triphosphate (ATP) resynthesis necessary to 
sustain skeletal muscle functions.
In addition, there is often impairment of the respiratory system in neuromuscular conditions, such as ALS. 
Nonetheless, even individuals with a well-advanced disease can have a ventilatory reserve sufficient to cope with 
maximal exercise6. In this regard, the respiratory system is able to adapt and triggers mechanisms of spontaneous 
compensatory respiratory plasticity that preserve breathing capacity, despite an impressive loss of respiratory 
motor neurons14. Once again however, even though pulmonary testing at rest can sometimes identify respiratory 
muscle impairments, the assessment of respiratory function during exercise is required to understand the contri-
bution of respiratory impairments to the heterogeneity of exercise intolerance in pALS.
The aim of this study was to evaluate, for the first time, the efficiency of the O2 transport-utilization chain (i.e., 
from lung ventilatory mechanics and diffusion, through cardiovascular O2 delivery to tissues, to O2 extraction at 
the muscles) during exhaustive exercise, requiring a large increase in the metabolic demands of skeletal muscles 
in pALS. The results will contribute to a better understanding of the complex, multifactorial pathogenesis of ALS, 
and to clarify when there is an early manifestation of oxidative metabolism impairment in pALS. We also investi-
gated if there was a correlation between clinical predictors of ALS progression and the measures obtained by this 
study, in order to evaluate if determinants of reduced exercise tolerance might match ALS clinical heterogeneity.
Materials and Methods
Participants. Following ethical committee approval (protocol #129, 10-JUN-2014, University of Milano-
Bicocca) and informed consent, 17 patients diagnosed with “possible” or “probable” ALS according to the revised 
El Escorial criteria were recruited15. They performed an exercise tolerance test at baseline (T0) and 4 months later 
(T1), and these results were compared with those of 13 healthy age- and sex- matched sedentary controls (CTRL, 
age 52.1 ± 10.6 yrs.; 11 M/2 F). Furthermore, all procedures and methods were performed in accordance with the 
relevant international guidelines on exercise testing to reduce any psychological or physical discomfort of partic-
ipants to a minimum. The data presented in this manuscript are part of the “ME_E_SLA” project (ClinicalTrials.
gov Identifier: NCT02548663).
Table 1 shows the demographic and clinical characteristics of pALS at T0. Patients were clinically character-
ized with the ALS functional rating scale-revised version (ALSFRS-R)15. The disease progression index (DPI) 
was estimated as the loss in ALSFRS-R score over time; i.e., difference of ALSFRS-R scores (T1-T0)/3 months16. 
Nutritional status was evaluated by the Mini Nutritional Assessment (MNA)17, where malnutrition ranges from 0 
to 16.5, risk of malnutrition from 17 and 23.5, and a normal nutrition status is defined by scores >24 (up to 30). 
The fat free mass (FFM) was calculated by measuring skinfolds at 7 sites (C10 Plicometer Tanner – Whitehouse; 
Holtain, Ltd., Crymych, UK), and applying the Jackson Pollock body density equation18, 19. The exclusion criteria 
for this study were: inability to pedal on a cycle-ergometer, unstable cardiac disease, acute infective disorders 
preventing the execution of the test, or resting arterial blood O2 saturation (SaO2) < 92%. At T1, 2 pALS dropped 
out due to apprehension in performing the cardiopulmonary exercise test (CPET, described below), and 1 pALS 
dropped out due to the caregiver’s personal reasons.
Cardiopulmonary exercise test. Each participant underwent to CPET on a cycle-ergometer (Ergomedic 
Monark LC6: Monark, Varberg-Sweden) under medical supervision, at baseline and only for pASL also after 4 
months. Electrocardiography was used in order to detect heart rhythm and frequency by 12-lead electrocardiog-
raphy monitoring (Quark C12x: Cosmed, Roma-Italy), and SaO2 was continuously recorded via pulse oximetry 
at the finger (RAD 9 Signal Extraction Pulse Oximeter: Masino Corporation, Irvine – California, USA). 
Confirmation that participants were in a resting condition before all tests was achieved by measuring heart rate 
(HR), tidal volume (Vt) and respiratory frequency (Rf) (i.e., pulmonary ventilation, VE, in BTPS). After 2 min-
utes of unloading pedaling the ramp steepness (either 3 or 5 or 10 or 15 W*min−1) was chosen empirically 
according to habitual activities of the pALS, as ascertained by a pre-test interview, and participants cycled until 
voluntary exhaustion was reached. “Exhaustion” was defined by the inability to maintain cycle rate despite vigor-
ous encouragement by the operators. The Borg scale scored the subjective perceived rate of exertion at exhaus-
tion20. Breath-by-breath VE, O2 uptake ( VO2) and CO2 output ( VCO2) were measured by a metabolic cart (Vmax 
Spectra 229: Sensormedics, Yorba Linda, CA-USA). The peak O2 consumption ( VO2peak) was determined: this 
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variable was intended as a descriptor of the overall efficiency of the O2 transport and utilization chain, and was 
used as a measure of exercise tolerance1. Capillary blood samples were obtained by puncturing the ear lobe before 
and at the end of the CPET (during the first 9 minutes of recovery), and blood lactate concentration was measured 
by a dual-channel analyzer (Biosen C-line Clinic: EKF Diagnostic, Cardiff-England). The peak value measured 
during 9 minutes of recovery was considered the peak lactate concentration.
Respiratory tests. Before the CPET each patient was asked to perform a spirometric test in both orthostat-
ism and clinostatism for the determination of forced vital capacity (FVC) and forced expiratory volume in the 
first second (FEV1). The diffusion lung capacity through the air blood barrier (DLCO) was also measured (Vmax 
Spectra 229: Sensormedics, Yorba Linda, CA-USA). DLCO measurements were performed at total lung capacity 
using a single-breath method and having participants inspire a gas mixture containing 0.3% CH4, 0.3% CO and 
20% O2. A visual evaluation of the expected spirometry and DLCO curves was performed, and the average of 
three consecutive and repeatable measures was used. All variables were expressed with respect to predicted values 
according to age, sex, and BMI.
Vastus lateralis near infrared spectroscopy. NIRS is a non-invasive method that allows for the monitor-
ing of tissue oxygenation using the principle that the near-infrared light absorption characteristics of haemoglobin 
(Hb) and myoglobin depend on their O2 saturation at different wavelengths (780 and 850 nm, respectively)11, 12. 
Light in the near-infrared spectrum readily penetrates skin, fat, and bone and is differentially absorbed by 
heme-containing molecules in underlying tissues - predominantly oxy (Δ[HbO2]) and de-oxyhemoglobin 
(Δ[HHb]). Decreases in Δ[O2Hb] and increases in Δ[HHb] were interpreted as evidence of a balance between 
delivery and extraction relative to the tissues under investigation. A 2-channel continuous wave NIRS was used 
to detect muscle oxygenation (Nimo: Nirox, Brescia, Italy). This system is not equipped to measure blood flow. 
The skeletal muscle NIRS probe was positioned on the distal end of the dominant thigh to monitor oxygenation 
changes in the vastus lateralis muscle. The probe was firmly placed on the skin (~10 cm above the proximal border 
of patella and 3 cm lateral to the midline of the thigh) and secured with a Velcro strap. The detector–illuminator 
distance was set at 3.5 cm. Elastic bandages were put around the probe to prevent contamination from localised 
light. Pen-marks were made over the skin to indicate the margins of the plastic spacer in order to check for any 
downward sliding of the probe during cycling. Once secured in place, no sliding of the probe was detected for 
any of the tests. Skinfold thickness at the site of application of the muscle NIRS probe was determined before 
the exercise protocol and the measured average values of skin and subcutaneous thigh tissue thickness in pALS 
and CTRL were 16.1 ± 9.2 mm (range 7.1–40.0) and 15.3 ± 8.7 mm (range 4.4–27.4), respectively. At the end of 
exercise a “physiological calibration” was performed by inducing a transient ischemia of the investigated limb, 
obtained by applying a wider cuff (tourniquet) to the proximal part of the thigh and inflating to 250–350 mmHg 
(depending on the participant’s body mass index). This manoeuvre needs 4 to 6 min and can be uncomfortable for 
some participants. The maximal de-oxygenation was considered when the increase in Δ[HHb] and the decrease 
in Δ[O2Hb] reached a “plateau”. Ischemia was obtained while individuals were sitting on the examination table. 
Individual extraction capacity was expressed as Δ[HHb]/Δ[HHb]isch.
Study design and statistical methods. This is an analytic observational case-control study (pALS versus CTRL). 
Values were expressed as means ± (SD). In order to estimate the necessary sample size, the results from a previous 
study regarding oxidative impairment in myopathies were used21, and a difference of 20% of Δ[HHb]peak in pALS 
compared to CTRL was a priori hypothesized: we estimated that a sample size of 15 participants would have been 
sufficient to obtain 80% power (α = 0.05).
A D’Agostino and Pearson omnibus normality test was used to check if values came from a Gaussian distri-
bution. The statistical significance of the difference in mean values between groups was evaluated by unpaired 
two-tailed Student’s t-tests if the data were normally distributed. Otherwise, the Mann-Whitney test was used 
(95% of confidence level). Regression and correlation analyses were performed using the least squared residuals 
method. The level of significance was set at p < 0.05. All statistical analyses were performed using a commercially 
available software package (Prism 6.0: GraphPad, La Jolla, CA, USA).
pALS n = 17
Age, y 52.2 ± 9.7 (39–70) Sex, F/M 3/14
BMI, kg/m2 25.6 ± 2.9 (18.7–29.9) EDC, definite/probable 10/7
FFM, kg 60.7 ± 11.2 (36.1–72.5) Onset, B/S 4/13
ALSFRS-R 37.1 ± 6.2 (26–46) NIV, no/yes 12/5
DET, months 13.7 ± 11.6 (1–48) EN, no/yes 0/17
*Disease duration, months 16.7 ± 14.8 (1–48) Riluzole, no/yes 4/13
DPI 1.2 ± 0.9 (0–3.6) MNA 20.7 ± 3.7 (11–26)
Table 1. Demographic and clinical characteristics of patients with amyotrophic lateral sclerosis (pALS). 
B = bulbar or S = spinal onset; BMI = body mass index; DET = diagnosis elapsed time (from disease onset); 
DPI = disease progression index; EDC = El Escorial diagnosis category; EN = enteral nutrition; FFM = fat 
free mass; ALSFRS-R = ALS Functional Rating Scale-Revised; MNA = mini nutritional assessment index; 
NIV = non-invasive ventilation. *From the diagnosis to study start. Data are shown as mean ± SD (range).
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Results
Exercise tolerance and muscle O2 extraction. At T0, exercise tolerance was significantly reduced ( V
O2peak ~44% lower) in pALS when compared with CTRL (18.5 ± 6.4 vs 33.1 ± 7.8 ml*kg−1*min−1; p < 0.0001, 
coefficient of variation 35 vs. 23%). This was paralleled by a 43% lower peak skeletal muscle oxidative function in 
pALS vs. CTRL (0.28 ± 0.24 vs. 0.49 ± 0.14; p < 0.01, coefficient of variation 86% vs. 28%). A linear regression 
between these variables was found at T0 and T1. Since the slopes and intercepts were not different at T0 and T1, 
it was possible to use pooled slope and intercept, as shown in Fig. 1 (r2 = 0.64, p < 0.0001). This correlation was 
not present in healthy controls (r2 = 0.02, p = 0.59). In Fig. 1 data are shown with the exclusion of 3 participants, 
due to objective and subjective limits of the NIRS technique12: 2 pALS had an excessively thick layer of subcuta-
neous fat (>1.5 cm) to permit the accurate assessment of skeletal muscle oxidative function; 1 pALS did not tol-
erate the leg-cuff ischemia maneuver. Two more pALS (1 at T0 and 1 at T1) experienced a technical problem with 
NIRS during the CPET. Globally, the following variables were significantly reduced at exercise exhaustion in 
pALS with respect to CTRL: (1) VO2peak, expressed as percentage of the predicted value according to age, sex, 
body mass and height, was ~41% lower (64.5% ± 18.4 vs. 108.4% ± 24.1, p < 0.0001); (2) VE peak was ~46% lower 
(53.0 ± 25.4 vs. 98.0 ± 27.4 l*min−1, p < 0.0001); (3) Vtpeak was ~36% lower (1.66 ± 0.72 vs. 2.62 ± 0.46 l; 
p < 0.0005); (4) peak power was ~38% lower (87.0 ± 47.0 vs. 140.2 ± 64.2 W, p < 0.02); (5) blood lactate concen-
tration was ~45% lower (3.8 ± 1.9 vs. 7.0 ± 2.9 mM, p < 0.003).
Muscle power and lactate concentration. Figure 2 shows the relationship between the capacity 
to express power during exercise on the cycle ergometer and blood lactate concentration; both variables are 
expressed relative to the metabolically active body mass (i.e., FFM, fat free mass). Most of pALS showed val-
ues more than one SD below the average for CTRL (left inferior quadrant), pointing to a clear-cut distribution 
between these two groups of participants. A strong linear regression between power and lactate was present in 
pALS (r2 = 0.50, p < 0.0001): the arrow indicates one single pALS with an atypical blood lactate concentration 
and a very low peak power output during the exercise. pALS with an efficient skeletal muscle oxidative function, 
as characterized by peak O2 extraction as measured with NIRS (>35), had a peak power output and blood lactate 
concentration similar to CTRL (Fig. 2).
Figure 1. Correlation between exercise tolerance ( VO2peak) and vastus lateralis O2 extraction at peak of exercise 
(Δ[HHb]/Δ[HHb]isch), in pALS (black line) and CTRL (broken line, not significant). White circles: pALS at 
baseline (T0); white squares: pALS after 4 months (T1); grey triangles: matched healthy CTRL.
Figure 2. Correlation between peak blood lactate concentration [La] and peak power at exhaustion, 
normalized for metabolic mass (fatty free mass, FFM), in pALS and CTRL. Four quadrants were defined by 
drawing dotted lines, according to one SD below the average for CTRL for both variables. White circles: pALS at 
baseline (T0); white squares: pALS after 4 months (T1); grey triangles: matched healthy CTRL; grey dot: pALS 
with vastus lateralis O2 extraction >35%. Black arrow indicates 1 patient with atypical behavior.
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Correlations with ALS clinical scores. Figure 3A shows a positive linear correlation between ALSFRS-R 
scores and VO2peak (since at T0 and T1 slopes and intercepts were not different, it was possible to calculate a 
pooled slope and intercept, r2 = 0.24, p < 0.005). The linear regression was stronger when only the pALS with 
bulbar onset were considered (r2 = 0,74, p < 0.012). A negative linear correlation was found also between DPI 
scores above 0.65 (severe progression and shorter survival time) and VO2peak (r2 = 0.30, p < 0.05; Fig. 3B). A cor-
relation was also observed between MNA score at T0 and ALSFRS-R scores (Fig. 3C). Only 4 pALS (23.5%) had 
normal MNA scores, while 11 (65%) were at risk of malnutrition and 2 (11.5%) were malnourished.
Pattern of breathing and respiratory tests. pALS presented different pattern of breathing during exer-
cise with respect to CTRL: Figure 4 shows the correlation between VO2 and pulmonary VE during exercise for 2 
representative participants (1 pALS and 1 CTRL) that displayed a typical pattern of breathing (i.e., similar to all 
the other participants belonging to the same category). The Rf individual iso-lines for both individuals are also 
shown. Three features can be highlighted on comparing pALS with CTRL: 1) in pALS, VE is increased by main-
taining, from the onset of exercise up to VO2peak, a relatively constant and extremely high Rf value (35–40 breaths 
per min). Conversely, in CTRL Rf started from normal values (10 breath per minutes) and increased constantly 
Figure 3. Panel (A) Correlation between VO2 values at exhaustion and clinical scores of ALS disease 
(ALSFRS-R questionnaire), recorded at baseline (T0) and after 4 months (T1). Patients with ALSFRS-R score 
lower than 39 (dotted line) had shorter survival time. The broken line is related only to pALS bulb. Panel (B) 
Correlation between VO2 peak and the change in ALSFRS_R score after 4 months (T1–T0). Patients with 
ALSFRS-R score higher than 0.65 (dotted line) had shorter survival time. Panel (C) Correlation between Mini 
Nutritional Assessment (MNA) questionnaire scores and ALSFRS-R at T0. Patients with 16.5 < MNA < 25 had 
a risk of malnutrition, while patients with MNA < 16.5 were malnourished. White circles: pALS at T0; white 
squares: pALS at T1; black triangles: pASL with bulbar onset (pALS bulb).
www.nature.com/scientificreports/
6Scientific RepoRts | 7: 2951  | DOI:10.1038/s41598-017-02811-z
until the 75% of VO2peak was reached, attaining 40 breath per minute only at the very end of exercise; 2) a higher 
VE was required in pALS, compared to CTRL, to maintain the same VO2; 3) both VO2peak and VEpeak were clearly 
limited in pALS compared to CTRL, with the Vt in pALS almost half that of CTRL. The subjective perceived 
exertion on the Borg scale, and SaO2, were the same for pALS and CTRL.
Figure 5 shows a strong correlation between FVC and muscle oxygen extraction capacity (since at T0 and 
T1 slopes and intercepts were not different, it was possible to calculate a pooled slope and intercept, r2 = 0.51, 
p < 0.0003): arrows indicate one pALS with bulbar onset incapable of correctly performing the spirometry 
maneuver because of laryngeal dysfunction.
In Table 2, FVC and FEV1 at T0 and T1, measured in ortho- and clinostatism (expressed as % of predicted 
value according to sex, age and height) are shown: values ranged from normal to a severe respiratory impairment, 
with on average, a ~15% deficiency of the same values measured in clinostatism (p < 0.0001 for both parameters); 
DLCO indices are ~15% reduced if compared to normal values, but not the Khrog index (DLCO relative to the 
available ventilatory area); impaired FVC and FEV1 (<85% of predicted), in ortho-, but especially in clinostatism, 
strongly related to the reduced VO2peak; FVC and FEV1, in ortho-, but especially in clinostatism, were strongly 
related to the ALSFRS-R scores.
Discussion
The novelty of this study resides in having explored the efficiency of the O2 delivery and utilization chain in pALS, 
from the ventilatory phase to muscles extraction when facing a large increase in the metabolic demand during 
exhaustive exercise. Previous studies provided limited evidence about the skeletal muscle oxidative function of 
pALS, due to the small increase in metabolic demand (workloads obtained by electrical stimulation)13. Our key 
novel finding consisted of providing an integrated analysis demonstrating impairments of the O2 chain in pALS: 
from reduced pulmonary ventilation, to lower muscle O2 oxidative function and VO2peak, lactate production and 
therefore total power output. These data appear relevant to clinical practice, since they provide evidence that the 
ALSFRS-R score fails to really correlate with the actual metabolic capacity of the patient.
Figure 4. Relationships between VO2 and ventilation ( VE) values during exercise in representative participants 
from the pALS (black squares) and CTRL (crosses) groups. Individually, iso-respiratory frequency (Rf) lines are 
indicated (pALS, continuous lines; CTRL, broken lines).
Figure 5. Correlation between orthostatic lung vital capacity (FVC) and vastus lateralis O2 extraction 
(Δ[HHb]/Δ[HHb]isch) at exhaustion, at baseline (T0) and after 4 months (T1), in pALS. White circles: 
pALS at T0; white squares: pALS at T1. Black arrow indicates 1 pALS with bulbar onset who was incapable of 
performing fully and correctly the spirometry maneuver.
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Consistent with the results of Mezzani et al.1, we report pALS to have a large (~40%) reduction in VO2peak once 
the diagnosis is established. We extend these findings with the observation that VO2peak values were 3-fold more 
heterogeneous in pALS compared to CTRL, presumably due to the variability in the clinical expression of muscle 
O2 extraction, and evolution of this disease.
According to Ryan et al., NIRS can be performed successfully in pALS and is a particularly sensitive technique 
to measure muscle O2 function in patients with denervated muscle13. In our study, lower NIRS values at exhaus-
tion in pALS were associated with poorer exercise tolerance, and those pALS expressing values within the normal 
range of oxidative function showed an exercise tolerance that was comparable to CTRL. Nevertheless, even pALS 
with a similar level of O2 extraction compared to CTRL were unable to achieve 100% of their predicted VO2peak. 
The strong limitation in exercise tolerance due to a low value of muscle oxidative function is not present in CTRL, 
suggesting the balance between O2 delivery and extraction is preserved.
NIRS measurements could provide an indirect assessment of mithocondrial disfunction in pALS13. Our 
results suggest that in pALS, a reduced O2 extraction at the skeletal muscles could be related to impaired mito-
chondrial oxidative function, possibly in a manner that is independent from motor neuron impairment22. As also 
reported by Al Sarray and colleagues22. our results support the view that additional stress (e.g., inflammation or, 
in our study, exercise) could unmask sub-clinical mitochondrial dysfunction in the muscle of pALS. Accordingly, 
exercise could provide an additional clinical tool to understand the complex pathogenesis of ALS.
In this study, both lactate concentration and power output normalized to the FFM was partially preserved in 
pALS with the highest values of muscle O2 extraction (as assessed by NIRS). As already observed in mitochon-
drial myopathies23, the lower blood lactate accumulation/concentration for the same workload and metabolic 
active mass (FFM) in pALS can be considered an index of an enhanced oxidative phosphorylation. Yet, in our 
pALS group, the lower lactate concentrations were found in patients displaying lower ability to extract O2 from 
their muscle. In pALS, these results suggest an individual heterogeneity in the expression of motor neuron disease 
(non-oxidative/oxidative motor unit recruitment), and a different contribution of less/more efficient oxidative 
fibers (Fig. 2). This is consistent with the observation that motor neuron death in pALS is different across motor 
pools24. The mechanisms underlying this heterogeneous response remain unknown, but it would be important to 
identify possible cellular/molecular differences, including diversities in oxidative metabolism, between suscepti-
ble versus resistant motor unit pools. NIRS evaluation in pALS could effectively explore oxidative metabolism and 
characterize the limits of oxidative function affecting individual exercise tolerance: it will be of interest to evaluate 
in a larger group of patients if a repeated follow up of the VO2peak versus O2 extraction relationship could have a 
prognostic value in pALS.
The CPET, in association with NIRS measurements, seems to add new information to assist the clinical follow 
up in pALS by examining the skeletal muscle oxidative function. The coefficient of variation of VO2peak values was 
especially elevated in patients with ALSFRS-R scores above 39, suggesting that in pALS, the clinical evaluation 
alone can hardly discriminate the real exercise tolerance otherwise measurable by CPET: some pALS considered 
“inefficient” at the ALSFRS-R showed a still residual capacity from the VO2peak point of view. Furthermore, only 
DPI above 0.65 are, in point of fact, related to a poor exercise tolerance, but some pALS with a low progression of 
disease (<0.25) were severely impaired regarding exercise tolerance. Kollewe and colleagues showed that 44% of 
pALS with a DPI < 0.25 will survive at least 5 years: our findings might possibly give reasons about those patients 
that, having the same DPI, nevertheless escape from this favorable survival rate16. In fact, the ALSFRS-R score 
alone, if compared to VO2peak measure, seems to be less sensitive to the real impairment of the efficiency of the O2 
transport and utilization chain and is –therefore– not useful to practice any hypothetical tailored exercise trial, 
aimed at individual and sustainable workloads. An exception to this consideration might be found for those pALS 
with bulbar onset where the ALSFRS-R scores were strongly correlated to VO2peak values. Notably, about 80% of 
pALS in this study had a risk of malnutrition or were malnourished, as revealed by the MNA evaluation. Both 
pALS_T0 pALS_T1 Regression with VO2* only values < 81%§
Regression with 
ALSFRS-R* only values < 81%§
FVC%-ortho 98.1 ± 26.2 (64–137) 98.6 ± 19.3 (69–133) r
2 = 0.02 p = 0.42 r2 = 0.44 p = 0.048 r2 = 0.31 p = 0.001 r2 = 0.01 p = 0.69
FEV1%-ortho 99.9 ± 27.9 (65–144) 104.3 ± 20.1 (75–138) r
2 = 0.01 p = 0.51 r2 = 0.47 p = 0.027 r2 = 0.38 p = 0.0005 r2 = 0.16 p = 0.23
FVC%-clino 84.9 ± 32.1 (24–125) 85.7 ± 31.3 (35–132) r
2 = 0.03 p = 0.39 r2 = 0.64 p = 0.001 r2 = 0.50 p < 0.0001 r2 = 0.31 p = 0.046
FEV1%-clino 88.0 ± 32.3 (24–129) 89.5 ± 31.9 (37–124) r
2 = 0.02 p = 0.48 r2 = 0.49 p = 0.01 r2 = 0.54 p < 0.0001 r2 = 0.27 p = 0.049
DLCO% 78.5 ± 9.3 (60–89) 86.0 ± 8.4 (73–101) r
2 = 0.05 p = 0.33 r2 = 0.51 p = 0.58 r2 = 0.05 p = 0.34 r2 = 0.01 p = 0.11
DLCO/VA% 101.8 ± 14.7 (66–119) 101.2 ± 12.9 (87–117) r
2 = 0.02 p = 0.58 N/A r2 = 0.00 p = 0.83 N/A
Table 2. Relationship between respiratory test parameters obtained during the CPET and clinical scores in 
pALS. T0, starting evaluation; T1, second evaluation after 4 months. *Since the slopes and intercepts where not 
significantly different at T0 and T1, it was possible to calculate one single pooled slope and intercept. §Linear 
regression analysis was performed again considering only spirometric or DLCO values < 81%. Statistically 
significant values are reported in bold. N/A, not applicable. FVC, Forced Vital Capacity; FEV1, Forced 
Expiratory Volume in 1 second, DLCO, Diffusion Lung Capacity.
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MNA and plicometry could be useful to define a correct dietary intake from the earliest onset of clinical manifes-
tation, in order to counteract the hypermetabolic state characteristic of the disease25, and especially if a tailored 
exercise program is advocated.
We also observed, especially for pALS with a severe impairment in clinostatism, a relationship between FVC 
and exercise tolerance. As known, FVC is a well-known prognostic factor in pALS, where FVC lower than 81% 
at first visit had a shorter median survival within 27 months16. However, we provide new information that FVC 
is also an important determinant of the reduced exercise tolerance in pALS due to the relationship between the 
reduced FVC and the muscle capacity of O2 extraction at the peak of exercise.
Since the primary insult in ALS is motor neuron death, the extent of the direct involvement of the respiratory 
muscle may be heterogeneous and the relatively spared respiratory motor neuron pools may compensate for the 
failure of the impaired ones14. Thus, we hypothesized that in some pALS respiratory muscle impairment may only 
become apparent when challenged during exercise. We observed a lower VE in pALS with the increase in VO2, 
essentially reflecting the inability to increase Vt, not compensated by the increase in Rf. This finding may reflect a 
reduced efficiency of inspiratory muscles to face the remarkable energy requirement to increase Vt, as well as their 
recruitment. While a NIRS evaluation directly on respiratory muscles is needed in order to effectively measure 
their oxidative function, it remains possible that the restrictive tendency of the chest wall compliance due to the 
weakness of respiratory muscles in pALS6, would require an increased metabolic demand by the respiratory mus-
cles. Thus, we may reason that reduced oxidative efficiency of respiratory muscles (as also seen in deconditioning) 
could be a limit when an adequate ventilatory reserve is necessary to maintain the ventilatory response to 
exercise.
The present data, revealing an inefficient skeletal muscle oxidative function can be explained on the basis of 
an incomplete activation of muscle fibers, due to the progressive impairment of motor neuron recruitment. Yet, 
a muscle deconditioning process related to exercise intolerance can further contribute to the metabolic derange-
ment. We consider this point critical, because specific mechanisms of exercise limitation in pALS are related to 
the requirement of a reduced pool of motor neurons to innervate a greater number of muscle fibers in the large 
muscle masses of the limbs and respiratory muscles. These macro-motor units become progressively less efficient 
due to the drop out of the chronically overloaded lower motor neurons and to the neuromuscular conduction 
defect along the reinnervated nerve sprouts6. Thus, our data support the hypothesis that severity of denervation 
and time since onset of the disease progressively impairing the oxidative function, both affect exercise tolerance 
and can be fully revealed only when the intensity of exercise requires a large increase in the metabolic demands 
of skeletal muscles in pALS.
Limitations. An intrinsic limitation of NIRS evaluation is the thickness of the fat layer under the probe posi-
tioned on the investigated muscle, as seen in sedentary women on the thigh or in participants displaying severe 
atrophy12. In all pALS, only the vastus lateralis muscle with the least functional impairment was investigated in 
order to avoid the possibility of severe atrophy under the probe. In addition, we placed the probe over the deeper 
muscle regions in the quadriceps muscle (where the greater proportion of oxidative fibers with more oxidative 
energy metabolism are presented)12. Otherwise, the area of muscle investigated by the NIRS probe may not rep-
resent, in terms of fiber types and motor unit recruitment pattern and/or fiber blood perfusion, a reliable assess-
ment of the whole muscle12, 13. However, it should be considered that the same limitation is intrinsically associated 
with all methods that investigate only a small portion of a muscle, including a muscle biopsy.
Conclusion
In summary, because of the difficulties in early diagnosis, and in the evaluation of disease progression, there is a 
growing need to identify clinically useful methods that can also aid to assess the impact of tailored rehabilitation 
interventions in pALS. Our results suggest that ALS is a disease with a multifactorial damage, not only related to 
the impaired recruitment of motor neurons. A heterogeneous manifestation of inefficient oxidative metabolism, 
at skeletal muscle level, is deeply related to the individual exercise capacity and function in pALS. Assessment of 
VO2peak and muscle oxygen extraction by NIRS might represent advantageous and non-invasive tools to evaluate 
the heterogeneous clinical expression of pALS. This findings have a putative prognostic value to be confirmed 
with a longitudinal evaluation.
Data availability. All raw data are available upon request to the corresponding Author (FL).
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